Thymosin Alpha-1: The Immune-Defense Peptide Behind Zadaxin

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide that the thymus gland uses to help train and direct the immune system, and it is the active ingredient in the prescription drug Zadaxin, approved in dozens of countries to treat chronic hepatitis. Unlike most "research peptides" in the biohacking world, Tα1 is a real, marketed medicine abroad, which makes its US status the confusing part: it has never been FDA-approved here, and the vials sold online to Americans are unregulated.

If you have seen Thymosin Alpha-1 promoted for immune support, COVID recovery, or "anti-aging," this guide is the high-level map of the whole compound, and it sits among the options in our best peptides for recovery roundup. We cover what it actually is, how it modulates the immune system, what it is approved and studied for, the honest state of the COVID and sepsis evidence, the doses reported in trials, and its split legal status. One thing to clear up immediately: despite the shared name, Thymosin Alpha-1 is a completely different peptide from Thymosin Beta-4 (the parent of TB-500). Tα1 is about immune defense; Tβ4 is about tissue repair.

Key Takeaways

• Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid immune-modulating peptide derived from thymosin fraction 5, a thymus-gland extract; it was first characterized in 1977 (Wikipedia, "Thymalfasin", retrieved 2026-06-15).
• It is an approved medicine in over 30 countries under the brand Zadaxin (SciClone), mainly for chronic hepatitis B and C and as a vaccine adjuvant (DrugBank, "Thymalfasin (DB04900)", retrieved 2026-06-15).
• It is not FDA-approved in the United States. It has held orphan-drug designations but no full US approval, so domestic "research-use-only" vials are unregulated (RxList, "Zadaxin", retrieved 2026-06-15).
• Its job is immune modulation, not tissue repair. It promotes T-cell maturation, boosts dendritic cell and natural-killer-cell activity, and acts through Toll-like receptors to push a Th1 response (RxList, "Zadaxin", 2026; MDPI, Molecules, 2023).
• The approved hepatitis-B dose is 1.6 mg subcutaneously twice a week, run for 6 to 12 months; that figure is a real drug label, not a community guess (RxList, "Zadaxin", retrieved 2026-06-15).
• The COVID and sepsis evidence is mixed and unsettled. An early observational COVID study suggested lower mortality, but the definitive 2025 Phase-3 sepsis trial (TESTS) found no survival benefit (BMJ, 2025).

What is Thymosin Alpha-1?

Thymosin Alpha-1 is a small, naturally occurring peptide of 28 amino acids that the body uses to help mature and coordinate immune cells, and that is manufactured as the drug thymalfasin (brand name Zadaxin). It comes from the thymus, the gland that schools T-cells early in life. It is studied and used as an immune modulator rather than for muscle, joint, or wound healing.

Chemically, Tα1 is an acetylated 28-amino-acid chain (sequence Ac-SDAAVDTSSEITTKDLKEKKEVEEAEN) cleaved from a larger precursor protein, prothymosin alpha, and it was originally isolated from a thymus-gland extract called thymosin fraction 5 in 1977 (Wikipedia, "Thymalfasin", retrieved 2026-06-15). Because it occurs naturally in the body, it is better thought of as a hormone-like signaling peptide than as a lab-invented "research chemical." Its molecular weight is roughly 3,100 daltons, and its reported serum half-life is short, about two hours (RxList, "Zadaxin", retrieved 2026-06-15). If injectable peptides are new to you, start with how peptides work.

The single most important fact about Tα1 is its split identity. In much of the world it is a genuine, approved prescription medicine; in the United States it is not approved at all. Everything else in this guide should be read through that lens.

Citation capsule. Thymosin Alpha-1 (Tα1), generic name thymalfasin, brand Zadaxin, is a naturally occurring 28-amino-acid immune-modulating peptide (sequence Ac-SDAAVDTSSEITTKDLKEKKEVEEAEN, MW ~3,100 Da) cleaved from prothymosin alpha and first isolated from thymosin fraction 5 in 1977. It is approved in 30+ countries for chronic hepatitis but is not FDA-approved in the US. Source: Wikipedia, "Thymalfasin," 2026; DrugBank DB04900; PubChem CID 16130571; CAS 62304-98-7.

How does Thymosin Alpha-1 work?

Thymosin Alpha-1 works by tuning the immune system: it helps immature thymus cells mature into working T-cells, sharpens dendritic and natural-killer cells, and nudges the body toward a Th1 (antiviral, anti-tumor) response. It does not build tissue or grow blood vessels; its whole job is signaling to immune cells. This is the cleanest way to separate it from the repair peptides it gets confused with.

In plain terms, Tα1 acts like a coach for the immune team. It binds Toll-like receptors (notably TLR2 and TLR9) on immune cells, which switches on antiviral signaling and helps dendritic cells present threats more effectively (Innerbody, "Thymosin Alpha-1", retrieved 2026-06-15). The Zadaxin drug information states that Tα1 acts "to promote T-cell differentiation and maturation," increasing CD4+, CD8+, and CD3+ T-cell numbers and raising the production of immune messengers such as interferon-gamma and interleukin-2, while boosting natural-killer-cell activity (RxList, "Zadaxin", retrieved 2026-06-15).

Here is what each proposed action contributes, in simple terms:

• T-cell maturation: helps thymocytes become functional CD4+ and CD8+ T-cells, the cells that recognize and kill infected or abnormal cells.
• Dendritic cell activation: improves how the "sentinel" cells detect threats and present them to the rest of the immune system.
• Toll-like receptor signaling (TLR2 / TLR9): a 2023 review notes Tα1 binds Toll-like receptors and "enhances the response of Th1 lymphocytes," the antiviral arm of immunity (MDPI, Molecules, "Thymosin α1 in viral infectious diseases", 2023, retrieved 2026-06-15).
• Cytokine and NK-cell boost: raises interferon and interleukin output and natural-killer-cell activity, which is why it is studied as an antiviral and cancer-adjuvant agent.

The receptor-level deep dive (how TLR signaling and Th1/Th2 balance actually work) is its own topic. We keep it at overview level here and link out to how peptides work for the foundations.

What is Thymosin Alpha-1 used for?

Thymosin Alpha-1 is approved and used mainly for chronic hepatitis B and C and as a vaccine adjuvant, and it is studied (with much weaker evidence) for sepsis, COVID-19, certain cancers as an add-on, and general immune support. The approved uses and the experimental uses are very different in how strong the evidence is, and it is worth keeping them apart.

The established use is antiviral hepatitis treatment: as Zadaxin, Tα1 is approved in over 30 countries for chronic hepatitis B and C, where it is used to help the immune system clear the virus, sometimes alongside interferon (DrugBank, "Thymalfasin (DB04900)", retrieved 2026-06-15). It is also used as a vaccine adjuvant and immune enhancer, particularly in older or immunocompromised patients. Beyond those, the compound has been studied as supportive care in sepsis and severe infections and, during the pandemic, in COVID-19, but those uses are investigational and the results are mixed.

A quick overview of the areas Tα1 is used or studied for, and where the evidence stands:

Because each of these is a distinct future spoke, we keep them brief here. The honest headline: Tα1 has a solid approved role in hepatitis abroad, and a much more uncertain role everywhere else.

How strong is the evidence for Thymosin Alpha-1?

The evidence is strongest for chronic hepatitis (where it is an approved drug) and genuinely mixed for the headline "immune-boosting" uses like COVID and sepsis, where larger and better trials have often failed to confirm early positive signals. This is the gap to understand before treating Tα1 as a proven immune cure-all.

The hepatitis evidence is the reason it became a marketed medicine in the first place, accumulating decades of clinical use across many countries. The newer, hyped uses are where caution is needed. During the pandemic, an early retrospective study reported that severe COVID-19 patients treated with Tα1 had lower mortality than untreated patients, 11.1% versus 30.0%, by helping restore depleted lymphocytes (Liu et al., Clinical Infectious Diseases, 2020, retrieved 2026-06-15). That sounds dramatic, but it was a small, observational study of 76 patients, not a randomized trial, and a separate 2021 study found no benefit on T-cell counts (Frontiers in Immunology, 2021, retrieved 2026-06-15).

Why the sepsis story is a useful warning

The sepsis evidence is the clearest example of why "promising early data" is not the same as "proven." In 2013, the ETASS trial in Chinese hospitals reported a 28-day mortality of 26.0% with Tα1 versus 35.0% with control, a roughly 9-point absolute difference, though the result sat right at the edge of statistical significance (Critical Care, "ETASS", 2013, retrieved 2026-06-15). For years that borderline signal was cited as evidence Tα1 helps in sepsis. Then a much larger, better-designed trial put it to the test.

In 2025, the definitive Phase-3 TESTS trial enrolled 1,089 patients and found essentially no difference: 28-day all-cause mortality was 23.4% with Tα1 versus 24.1% with placebo, and the authors concluded there was "no clear evidence that thymosin α1 decreases 28-day all-cause mortality in adults with sepsis" (BMJ, "TESTS", 2025, retrieved 2026-06-15). This is the pattern to remember: a marginal early result that did not survive a rigorous large trial. It does not erase Tα1's approved hepatitis role, but it should sharply discount the "immune-booster for anything" marketing.

Our take: The most common mistake we see is citing the one favorable COVID or sepsis study and ignoring the larger ones that followed. Tα1 is a real drug with a real approved indication, but the leap from "approved for hepatitis" to "boosts your immune system against everything" is exactly the leap the evidence does not support in 2026.

What doses of Thymosin Alpha-1 are reported and studied?

For its approved use, Thymosin Alpha-1 has a real label dose: 1.6 mg injected under the skin twice a week, run for several months for hepatitis B; the doses studied for sepsis and COVID were higher and more frequent. Because these are approved or trial figures rather than community guesses, they are more concrete than for most research peptides, but they are still not a recommendation for you to self-administer.

The approved hepatitis-B regimen on the Zadaxin label is 1.6 mg (about 900 micrograms per square meter of body surface) given subcutaneously twice a week for 6 to 12 months (RxList, "Zadaxin", retrieved 2026-06-15). In the sepsis trials, the regimen was more intensive, with 1.6 mg given subcutaneously twice daily for the first several days before tapering (Critical Care, "ETASS", 2013, retrieved 2026-06-15). COVID studies generally used 1.6 mg once or twice daily. We label all non-hepatitis figures as "studied in trials," because outside the approved hepatitis indication there is no validated dose, and the US sells no approved product at all.

The detailed titration, reconstitution math, and injection technique are a dedicated future spoke. We cover only the high-level framing here and link out to the general peptide foundations guide and quality checks.

For orientation only, here is how the reported regimens compare (not a recommendation):

Our take: The 1.6 mg twice-weekly hepatitis figure is unusually trustworthy for a peptide, because it is a real drug label rather than a forum convention. But that does not transfer to the experimental uses, where doses came from individual trials, not approved guidance, and where there is no FDA-approved product in the US to standardize anything.

How is Thymosin Alpha-1 different from TB-500 (Thymosin Beta-4)?

Thymosin Alpha-1 and TB-500 (a fragment of Thymosin Beta-4) share only the word "thymosin"; they are entirely different peptides with different jobs. Tα1 modulates the immune system, while Tβ4/TB-500 binds actin to drive tissue repair. Confusing them is the single most common mix-up, partly because both were originally found in the same thymus extract.

The names trace back to thymosin fraction 5, a crude thymus-gland extract from which many different peptides were later separated and independently sequenced. Thymosin Alpha-1 turned out to be a 28-amino-acid immune modulator. Thymosin Beta-4 is a larger, 43-amino-acid protein whose main role is sequestering actin, a structural protein inside cells, which helps cells migrate and rebuild damaged tissue (Wikipedia, "Thymosin beta-4", retrieved 2026-06-15). TB-500 is a synthetic fragment of that Tβ4 protein, sold as a research peptide for recovery. So Tα1 is the immune peptide and Tβ4/TB-500 is the repair peptide, and they are not interchangeable.

That is the hub-level contrast, kept deliberately brief. The full TB-500 story, its actin mechanism, dosing, and the "Wolverine stack," is its own article: see the complete TB-500 (Thymosin Beta-4) guide.

Is Thymosin Alpha-1 safe and legal?

Thymosin Alpha-1 has a generally reassuring safety record as an approved drug abroad, but its legal status is split: it is a prescription medicine in over 30 countries and is not FDA-approved in the United States, where the versions sold online are unregulated "research" products. That split is the most important practical point for a US reader.

On safety, Tα1 has been used clinically for decades in its approved markets and is generally described as well tolerated, with the most common issues being mild injection-site reactions (RxList, "Zadaxin", retrieved 2026-06-15). That track record is genuinely stronger than for most "research peptides." But "well tolerated as a supervised prescription drug abroad" is not the same as "safe to buy online and self-inject in the US," where there is no approved product, no pharmacist oversight, and no guarantee of what is actually in an unregulated vial. A persistent and false claim circulates online that Tα1 is "the only FDA-approved thymosin drug"; it is not approved by the FDA at all.

On legality, the picture depends entirely on where you are. In its approved markets it is a normal prescription medicine. In the US it has held only orphan-drug and investigational status, never full approval, so domestic vials are sold "for research use only, not for human consumption," which carries the same quality and contamination risks as any unregulated peptide. For the broader legal framework and how to evaluate a source, see are peptides legal and how to vet peptide quality.

Our take: Tα1 sits in an unusual spot. It is a legitimate, approved medicine somewhere, which makes it tempting to assume the online "research" version is equally safe and legitimate. In the US it is neither approved nor regulated, and "approved in China or Italy" does not make a gray-market American vial trustworthy.

How do people obtain Thymosin Alpha-1?

In its approved markets people get Thymosin Alpha-1 by prescription as Zadaxin; in the US, where it is not approved, people typically buy unregulated "research-use-only" vials online, a legal and quality gray market. There is no standard US prescription route for an unapproved drug outside a clinical trial.

Abroad, the legitimate path is a clinician prescribing Zadaxin for an approved indication such as hepatitis B. In the US, the searches usually end at research-peptide vendors selling lyophilized Tα1 "for research use only," which buyers reconstitute and use off-label. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight. Some US wellness clinics have offered it via compounding, but its status as an unapproved drug makes that legally fraught.

If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it. See how to vet peptide quality.
3. Understand handling and reconstitution before anything else; lyophilized peptides need correct mixing and cold storage. See how peptides work.
4. Talk to a qualified clinician who can weigh your specific health situation, interactions, and contraindications.

We are describing what people do, not endorsing it. Using an unapproved version of a drug means accepting unknown quality and risk with no regulatory safety net.

A realistic look at expectations

Thymosin Alpha-1 is a real immune-modulating drug with a proven role in hepatitis, but the broad "boost your immune system against anything" promise is not supported by the strongest evidence, so expectations for general immune use should be modest. Calibration matters here more than usual, because the approved-drug halo makes the hype sound more credible than it is.

Two honest caveats sit on top of the marketing. First, an approved use for hepatitis does not validate the experimental uses; the largest sepsis trial was negative, and the COVID data are observational and conflicting. Second, "immune support" is famously hard to measure, so subjective improvements are easy to attribute to a peptide that may be doing nothing measurable. For grounded context on reading transformation and benefit claims, see peptides before and after.

Frequently Asked Questions

The bottom line

Thymosin Alpha-1 is the rare peptide in this space that is genuinely a medicine. As Zadaxin, it is approved in dozens of countries for chronic hepatitis and used as an immune and vaccine adjuvant, with a real drug label, a known dose, and decades of clinical use behind it. Its mechanism, coaching T-cells and dendritic cells toward a stronger antiviral response, is well characterized, and that is why it earns a different kind of respect than the average "research chemical."

The discipline is in not over-extending that credibility. It is not FDA-approved in the United States, the online "research" vials are unregulated, and the headline immune-boosting uses are far less settled than the marketing implies; the largest sepsis trial was flatly negative and the COVID data are observational. And it is not TB-500: Tα1 is the immune peptide, Tβ4/TB-500 is the repair peptide. If you take one thing from this hub, let it be the gap between "approved for hepatitis somewhere" and "proven to boost your immune system here." From here, the natural next reads are TB-500 (Thymosin Beta-4), how to vet peptide quality, and are peptides legal.

Sources

• Wikipedia. "Thymalfasin." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Thymalfasin
• Wikipedia. "Thymosin beta-4." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Thymosin_beta-4
• DrugBank. "Thymalfasin (DB04900)." Retrieved 2026-06-15. https://go.drugbank.com/drugs/DB04900
• RxList. "Zadaxin (Thymalfasin) Drug Information." Retrieved 2026-06-15. https://www.rxlist.com/zadaxin-drug.htm
• "Thymosin α1: A Comprehensive Review of the Literature." Molecules (MDPI), 2023. Retrieved 2026-06-15. https://www.mdpi.com/1420-3049/28/8/3539
• Liu Y, Pan Y, Hu Z, et al. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells." Clinical Infectious Diseases, 2020;71(16):2150-2157. Retrieved 2026-06-15. https://academic.oup.com/cid/article/71/16/2150/5842185
• "Thymosin Alpha 1 Therapy in Critically Ill Patients With COVID-19." Frontiers in Immunology, 2021. Retrieved 2026-06-15. https://www.frontiersin.org/articles/10.3389/fimmu.2021.568789/full
• Wu J, et al. "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial." Critical Care, 2013;17:R8. Retrieved 2026-06-15. https://ccforum.biomedcentral.com/articles/10.1186/cc11932
• "The efficacy and safety of thymosin α1 for sepsis (TESTS): a multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial." BMJ, 2025. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/39814420/
• Innerbody Research. "Thymosin Alpha-1." Retrieved 2026-06-15. https://www.innerbody.com/thymosin-alpha-1-peptide
• PubChem. "Thymalfasin (CID 16130571)." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/16130571